Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $19 | $17 | $24 | $29 |
| G&A Expenses | $8 | $7 | $8 | $10 |
| SG&A Expenses | $8 | $7 | $8 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $28 | $23 | $33 | $39 |
| Operating Income | -$28 | -$23 | -$33 | -$39 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$35 | -$4 | -$9 | -$5 |
| Pre-Tax Income | -$62 | -$27 | -$41 | -$43 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$62 | -$27 | -$41 | -$43 |
| % Margin | – | – | – | – |
| EPS | -1.02 | -0.563 | -0.89 | -1.03 |
| % Growth | -81.2% | 36.8% | 13.6% | – |
| EPS Diluted | -1.02 | -0.563 | -0.89 | -1.03 |
| Weighted Avg Shares Out | 61 | 48 | 47 | 42 |
| Weighted Avg Shares Out Dil | 61 | 48 | 47 | 42 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$27 | -$23 | -$32 | -$38 |
| % Margin | – | – | – | – |